linjc16/ctgov huggingface dataset:
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis

Study Overview
=================
Brief Summary
-----------------
The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis. The investigators analysis the correlation of gene mutation and the disease course.

Detailed Description
-----------------
The investigators collected the data from from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis. The investigators analysis the correlation of gene mutation and the disease course. The investigators use Kaplan-Meier regression to analyze the overall survival, and the difference between the groups was calculated using log rank test. Cox proportional hazards method was used to create the regression model and estimate the hazard ratios.

Official Title
-----------------
Genomic Analysis in Surgically Treated NSCLC Brain Metastasis Based on Neurosurgical Perspectives

Conditions
-----------------
NSCLC Stage IV, Brain Metastases

Intervention / Treatment
-----------------
* Procedure: craniectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - patients diagnosed with non-small cell lung cancer who underwent craniectomy and subsequent whole brain radiotherapy and associated chemo or target therapy Exclusion Criteria: patient who did not receive postoperative adjuvant therapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: craniectomy|craniectomy outcomes and survival|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative survival |  | From date of craniectomy until the date of patient deceased or date of last followed medical record, with median follow up around to 20 months |
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).

Detailed Description
-----------------
Phase I: The purpose of this study was to determine which of the subcutaneous doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of the study. Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due to a change in product development strategy

Official Title
-----------------
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.

Conditions
-----------------
Myelodysplastic Syndrome

Intervention / Treatment
-----------------
* Drug: Subcutaneous Decitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Confirmed diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia (CMML). Exclusion Criteria: Prior therapy with decitabine or azacytidine (Vidaza). Experimental or standard drugs for the treatment of MDS within 28 days of the first day of study drug treatment. Clinically significant anemia. Prior history of malignancy other than MDS. Any active infection. Radiotherapy within 14 days prior to study enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DACO-019 2mg/m^2<br>DACO-019 2mg/m^2 twice daily (BID) | Drug: Subcutaneous Decitabine<br> <br> |
| Experimental: DACO-019 5mg/m^2<br>DACO-019 5mg/m^2 BID | Drug: Subcutaneous Decitabine<br> <br> |
| Experimental: DACO-019 10mg/m^2<br>DACO-019 10mg/m^2 BID | Drug: Subcutaneous Decitabine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phase I: To determine which of the subcutaneous (SQ) doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS. |  | Up to 8 cycles (224 days) | 
| Phase II: To evaluate hematological response at the dose selected in the Phase I portion of the study. |  | Up to 12 cycles (336 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myelodysplastic Syndrome, MGI Pharma, Decitabine, Dacogen
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the benefit of thrombus aspiration in patients with ST-elevation myocardial infarction presenting late after symptom onset.

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Device: manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ST-elevation myocardial infarction >12 and <48 hours after symptom onset age 18 to 90 years informed consent Exclusion Criteria: prior fibrinolysis severe comorbidities with limited life expectancy pregnancy patient unable to give informed consent participation in another trial contraindications for heparin, aspirin or thienopyridines contraindications for cardiac magnetic resonance examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: thrombus aspiration<br>Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA) | Device: manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)<br>* manual thrombus aspiration catheter to be used during percutaneous coronary intervention<br>|
| No Intervention: no thrombus aspiration<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microvascular obstruction (cardiac magnetic resonance imaging) |  | 1-4 days after randomization |
The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention

Study Overview
=================
Brief Summary
-----------------
The first step in any clinical intervention against obesity involves sustained lifestyle changes. Researcher can use these strategies to beneficial the effects of weight and on cardiovascular risk. The researcher develope methods for assessing the effectiveness use optical technology to make such assessments, specifically in the area of fatty tissue can predict the effectiveness of the intervention in causing weight reduction and treating metabolic disease.

Detailed Description
-----------------
Optical technologies under development at the Beckman Laser Institute. Diffuse Optical Spectroscopy Imaging is a method for studying absorption and scattering (optical properties) of tissue in humans. It is related to near-infrared spectroscopy , but allows for more quantitative and thorough measurements. The researcher use Diffuse Optical Spectroscopy to measure fatty tissue, water, blood concentration level during weight loss program to determine the effect of sustained changes in weight or relapses.

Official Title
-----------------
The Use of Diffuse Optical Spectroscopy to Characterize Adipose Tissue Oxygenation and Vascular Reactivity in Response to Weight-Loss Intervention

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Other: Weight Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body Mass Index greater than 25, overweight Participation in Weight Loss program Exclusion Criteria: A medical history of myocardial infarction or cerebrovascular stroke Pregnancy or planned pregnancy during the course of the study period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Weight Control<br>Weight Control | Other: Weight Control<br>* Weight Control<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight Control |  | 3 months |
Clinical Characteristics of Patients Under the Age 21 Years Who Underwent Gynecological Surgery

Study Overview
=================
Brief Summary
-----------------
Young patients with adnexal lesions may have variable presenting symptoms. In this study, we reviewed the clinical characteristics of young Korean patients who took the operation in university hospital with adnexal lesions over the past 14 years.

Detailed Description
-----------------
The incidence of gynecologic surgery during the pediatric and adolescent period remains low. In this age group, the causes of gynecologic surgery were usually divided into three parts, congenital anomalies, genital traumas, and pathologic lesions of genital tract including uterine bady and cervix, ovaries, fallopian tubes, vagina, and vulva. Among these, adnexal masses generally have been the most common cause of gynecologic surgery in the pediatric and adolescent patients. Adnexal lesions span a spectrum of pathology from functional (non-neoplastic), benign to highly aggressive malignant neoplasms. The actual incidence of adnexal lesions in the young women is unknown; however, of the ovarian neoplasms operated on during childhood or adolescence, 10-30% are malignant. Therefore, early detection and adequate management of adnexal lesions are prerequisite for the life saving and future preservation of fertility potential. But until now, there have been limited studies regarding the clinical characteristics of patients with adnexal mass during this period, and most studies have been conducted with small numbers of patients. Therefore, more informations regarding the clinical characteristics of patients with adnexal lesions are very important for the early diagnosis and adequate management of the adnexal lesions in children and adolescents. In this study, we reviewed the clinical characteristics of 494 young Korean patients who took the operation in university hospital with adnexal lesions over the past 14 years.

Official Title
-----------------
Clinical Characteristics of Adnexal Masses in Korean Pediatric and Adolescent Patients Under the Age 21 Years

Conditions
-----------------
Demographic Findings, Presenting Symptoms on First Hospital Visit, Preoperative Radiologic Findings, Operation Method, Histologic Findings

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Young women up to 20 years of age who took the gynecologic surgery due to adnexal lesions at the department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea from January, 1995 through March, 2009 were included.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP

Study Overview
=================
Brief Summary
-----------------
assess the safety and effectiveness of using low-flow extracorporeal membrane oxygenation(CO2 removal) driving by CVVH machine in the severe NCP patients

Official Title
-----------------
Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation（CO2 Removal） Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)

Conditions
-----------------
COVID-19, ECMO

Intervention / Treatment
-----------------
* Device: Low flow ECMO driving by CVVH machine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. NCP with severe acute respiratory distress syndrome with ratio of partial pressure of arterial oxygen over fraction of inspired oxygen (PaO2:FiO2)<150 and PEEP >10cmH2O 2. Driving pressure> 20cmH2O 3. RR>30bpm 4.PaCO2>55cmH2O and/or PH>7.3 Exclusion Criteria: 1. poor venous vascular condition and unavaible for central venous catheter placement

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NCP patient with severe ARDS and/or high ventilator supported<br>The NCP patient with severe ARDS and/or high ventilator supported condition was eligibilitable for enrollment | Device: Low flow ECMO driving by CVVH machine<br>* With aim to clear CO2 and improve oxygenation, a low flow ECMO treatment(using oxgyenator membrane of kid type ) driving by CVVH machine will be performed in the NCP with severe ARDS<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PaCO2 | PaCO2 from blood gas analysis | Day 1 | 
| Driving Pressure | Driving Pressure monitor by ventilator | Day 1 | 
| Tidal volume | Tidal volume monitor by ventilator | Day 1 |
All-ceramic Crowns in Patients With Sleep Bruxism

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the complication rate of 2 types of all-ceramic crowns in patients with or without bruxism.

Official Title
-----------------
All-ceramic Crowns in Patients With Sleep Bruxism - a Randomized Clinical Trial

Conditions
-----------------
Sleep Bruxism, Monolithic Ceramic Fixed Dental Prosthesis (Single Crowns)

Intervention / Treatment
-----------------
* Device: Zirconia crowns (Prettau®)
* Device: lithium disilicate crowns (IPSe.max®)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: need a molar crown tooth antagonist (no implant) Exclusion Criteria: no Antagonist pregnancy, bleeding, periodontal diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bruxism + lithium disilicate crown<br>Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate. | Device: lithium disilicate crowns (IPSe.max®)<br>* lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism<br>|
| Experimental: No bruxism + lithium disilicate crown<br>Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate. | Device: lithium disilicate crowns (IPSe.max®)<br>* lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism<br>|
| Experimental: Bruxism + zirconia crown<br>Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia. | Device: Zirconia crowns (Prettau®)<br>* Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism<br>|
| Experimental: No bruxism + zirconia crown<br>Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia. | Device: Zirconia crowns (Prettau®)<br>* Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of all-ceramic crowns as determined by complication rate | In this study, a complication is defined as any event happening at the study crown or the supporting tooth that requires a clinical intervention. | up to 5 years |
18842 - Sun Protection Factor Assay

Study Overview
=================
Brief Summary
-----------------
To evaluate the Sun Protection Factor (SPF) efficacy on human skin.

Official Title
-----------------
Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose

Conditions
-----------------
Sunscreening Agent

Intervention / Treatment
-----------------
* Drug: Coppertone (BAY987517)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing. Male and female Aged between 18-70 years old. Good health as determined from the HRL SHF Signed and dated Informed Consent Form Signed and dated HIPAA Form An unambiguous MED or MPPD (Minimal Persistent Pigment Darkening Dose) Exclusion Criteria: Subjects on test at any other research laboratory or clinic. Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light. Pre-existing dermatologic conditions which have been diagnoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study. Pre-existing other medical conditions (e.g. adult asthma. diabetes). Treatment with antihistamines or corticosteroids within one week prior to initiation of the test. Treatment with antibiotics within two weeks prior to initiation of the test. Chronic medication which could affect the results of the study. Known pregnant or nursing women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BAY987517<br>Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application | Drug: Coppertone (BAY987517)<br>* Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-08)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Minimal Erythema Dose (MED) |  | Up to 15 minutes | 
| Minimal Persistent Pigment DArkening Dose (MPPD) |  | Up to 15 minutes |
Cardiac Water and Fluoromethane Cardiac PET

Study Overview
=================
Brief Summary
-----------------
In this study we are looking at the blood flow to the heart using two different chemical tags or tracers that give off a low level of radiation. The tracers used in this study are called O15-water and F17-fluoromethane. These tracers mix with the blood and will move through the body. The researchers will use positron emission tomography (PET scans)to track the tracers as they moe through the heart and chest.

Official Title
-----------------
Comparison of Cardiac Perfusion by O15-water and F17-fluoromethane PET

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Procedure: Cardiac PET imaging- rest and pharmacological stress


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Age 18 to 40 years old 2. Willing to provide written informed consent Exclusion Criteria: 1. A history of CAD 2. A history of active bronchospasm or asthma on theophylline bronchodilators 3. A history of any cardiac risk factors including: HTN, Diabetes, Hyperlipidemia, Smoking, and premature CAD in immediate family member 4. A history of liver disease or other significant disease 5. Females who are pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Cardiac PET imaging- rest and pharmacological stress|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| -- implement myocardial perfusion quantification for O15-labeled water at rest and with pharmacologic stress, |  | assess at time of PET scan | 
| -- determine the biodistribution of fluoromethane in the thorax to see if it is usable for a cardiac perfusion tracer, |  | assess at time of PET Scan | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| --develop initial methods for quantification of myocardial perfusion if applicable for labeled fluoromethane. |  | assess at time of PET scan | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac PET imaging, Radiopharmaceutical tracers